Cargando…
Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning
Increase in global population and growing disease burden due to the emergence of infectious diseases (Zika virus), multidrug-resistant pathogens, drug-resistant cancers (cisplatin-resistant ovarian cancer) and chronic diseases (arterial hypertension) necessitate effective therapies to improve health...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192146/ https://www.ncbi.nlm.nih.gov/pubmed/28200013 http://dx.doi.org/10.1093/bib/bbw136 |
_version_ | 1783363851448745984 |
---|---|
author | Shameer, Khader Glicksberg, Benjamin S Hodos, Rachel Johnson, Kipp W Badgeley, Marcus A Readhead, Ben Tomlinson, Max S O’Connor, Timothy Miotto, Riccardo Kidd, Brian A Chen, Rong Ma’ayan, Avi Dudley, Joel T |
author_facet | Shameer, Khader Glicksberg, Benjamin S Hodos, Rachel Johnson, Kipp W Badgeley, Marcus A Readhead, Ben Tomlinson, Max S O’Connor, Timothy Miotto, Riccardo Kidd, Brian A Chen, Rong Ma’ayan, Avi Dudley, Joel T |
author_sort | Shameer, Khader |
collection | PubMed |
description | Increase in global population and growing disease burden due to the emergence of infectious diseases (Zika virus), multidrug-resistant pathogens, drug-resistant cancers (cisplatin-resistant ovarian cancer) and chronic diseases (arterial hypertension) necessitate effective therapies to improve health outcomes. However, the rapid increase in drug development cost demands innovative and sustainable drug discovery approaches. Drug repositioning, the discovery of new or improved therapies by reevaluation of approved or investigational compounds, solves a significant gap in the public health setting and improves the productivity of drug development. As the number of drug repurposing investigations increases, a new opportunity has emerged to understand factors driving drug repositioning through systematic analyses of drugs, drug targets and associated disease indications. However, such analyses have so far been hampered by the lack of a centralized knowledgebase, benchmarking data sets and reporting standards. To address these knowledge and clinical needs, here, we present RepurposeDB, a collection of repurposed drugs, drug targets and diseases, which was assembled, indexed and annotated from public data. RepurposeDB combines information on 253 drugs [small molecules (74.30%) and protein drugs (25.29%)] and 1125 diseases. Using RepurposeDB data, we identified pharmacological (chemical descriptors, physicochemical features and absorption, distribution, metabolism, excretion and toxicity properties), biological (protein domains, functional process, molecular mechanisms and pathway cross talks) and epidemiological (shared genetic architectures, disease comorbidities and clinical phenotype similarities) factors mediating drug repositioning. Collectively, RepurposeDB is developed as the reference database for drug repositioning investigations. The pharmacological, biological and epidemiological principles of drug repositioning identified from the meta-analyses could augment therapeutic development. |
format | Online Article Text |
id | pubmed-6192146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61921462018-10-23 Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning Shameer, Khader Glicksberg, Benjamin S Hodos, Rachel Johnson, Kipp W Badgeley, Marcus A Readhead, Ben Tomlinson, Max S O’Connor, Timothy Miotto, Riccardo Kidd, Brian A Chen, Rong Ma’ayan, Avi Dudley, Joel T Brief Bioinform Paper Increase in global population and growing disease burden due to the emergence of infectious diseases (Zika virus), multidrug-resistant pathogens, drug-resistant cancers (cisplatin-resistant ovarian cancer) and chronic diseases (arterial hypertension) necessitate effective therapies to improve health outcomes. However, the rapid increase in drug development cost demands innovative and sustainable drug discovery approaches. Drug repositioning, the discovery of new or improved therapies by reevaluation of approved or investigational compounds, solves a significant gap in the public health setting and improves the productivity of drug development. As the number of drug repurposing investigations increases, a new opportunity has emerged to understand factors driving drug repositioning through systematic analyses of drugs, drug targets and associated disease indications. However, such analyses have so far been hampered by the lack of a centralized knowledgebase, benchmarking data sets and reporting standards. To address these knowledge and clinical needs, here, we present RepurposeDB, a collection of repurposed drugs, drug targets and diseases, which was assembled, indexed and annotated from public data. RepurposeDB combines information on 253 drugs [small molecules (74.30%) and protein drugs (25.29%)] and 1125 diseases. Using RepurposeDB data, we identified pharmacological (chemical descriptors, physicochemical features and absorption, distribution, metabolism, excretion and toxicity properties), biological (protein domains, functional process, molecular mechanisms and pathway cross talks) and epidemiological (shared genetic architectures, disease comorbidities and clinical phenotype similarities) factors mediating drug repositioning. Collectively, RepurposeDB is developed as the reference database for drug repositioning investigations. The pharmacological, biological and epidemiological principles of drug repositioning identified from the meta-analyses could augment therapeutic development. Oxford University Press 2017-02-15 /pmc/articles/PMC6192146/ /pubmed/28200013 http://dx.doi.org/10.1093/bib/bbw136 Text en © The Author 2016. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Paper Shameer, Khader Glicksberg, Benjamin S Hodos, Rachel Johnson, Kipp W Badgeley, Marcus A Readhead, Ben Tomlinson, Max S O’Connor, Timothy Miotto, Riccardo Kidd, Brian A Chen, Rong Ma’ayan, Avi Dudley, Joel T Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning |
title | Systematic analyses of drugs and disease indications in RepurposeDB reveal
pharmacological, biological and epidemiological factors influencing drug
repositioning |
title_full | Systematic analyses of drugs and disease indications in RepurposeDB reveal
pharmacological, biological and epidemiological factors influencing drug
repositioning |
title_fullStr | Systematic analyses of drugs and disease indications in RepurposeDB reveal
pharmacological, biological and epidemiological factors influencing drug
repositioning |
title_full_unstemmed | Systematic analyses of drugs and disease indications in RepurposeDB reveal
pharmacological, biological and epidemiological factors influencing drug
repositioning |
title_short | Systematic analyses of drugs and disease indications in RepurposeDB reveal
pharmacological, biological and epidemiological factors influencing drug
repositioning |
title_sort | systematic analyses of drugs and disease indications in repurposedb reveal
pharmacological, biological and epidemiological factors influencing drug
repositioning |
topic | Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192146/ https://www.ncbi.nlm.nih.gov/pubmed/28200013 http://dx.doi.org/10.1093/bib/bbw136 |
work_keys_str_mv | AT shameerkhader systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT glicksbergbenjamins systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT hodosrachel systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT johnsonkippw systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT badgeleymarcusa systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT readheadben systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT tomlinsonmaxs systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT oconnortimothy systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT miottoriccardo systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT kiddbriana systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT chenrong systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT maayanavi systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning AT dudleyjoelt systematicanalysesofdrugsanddiseaseindicationsinrepurposedbrevealpharmacologicalbiologicalandepidemiologicalfactorsinfluencingdrugrepositioning |